Metastatik endometrioid endometrial karsinom hastalarında tedavi seçeneklerinin sağkalım üzerine etkisi
Loading...
Date
2022
Authors
Ocak, Birol
Journal Title
Journal ISSN
Volume Title
Publisher
Bursa Uludağ Üniversitesi
Abstract
Endometrium kanseri (EK) gelişmiş ülkelerde en sık görülen jinekolojik kanserdir. Obezite en önemli risk faktörü olarak kabul edilmektedi r. Endometrium kanserleri içerisinde en sık görülen alt tip endometrioid endometrial karsinomdur (EEK). Çalışmamızda metastatik EEK hastalarının demografik ve klinikopatolojik özelliklerini, kullanılan tedavi yöntemlerinin sağ kalıma etkisini incelemeyi amaçladık. Hastaların medyan yaşı 58 (39,4-81,9) idi. On altı hastanın hastaneye başvuru şikayeti vajinal kanamaydı. Medyan takip süresi 43 (0,2- 104,3) aydı. Hastaların medyan progresyonsuz sağkalım (PS) süresi 39,9 ay (%95 güven aralığı (GA): 35,0-79,1), medyan genel sağkalım (GS) süresi 59,1 ay (%95 GA: 39,1-80,8) saptandı. Kemoradyoterapi alan hastaların PS ve GS süresi sadece kemoterapi ile tedavi edilen hastalara göre istatistiksel anlamlı olarak daha uzundu (log-rank testi, PS için p=0,012, GS için p=0,015). Çalışmamız metastatik evrede seçilmiş hasta grubunda kemoradyoterapinin tercih edilebileceğini desteklemektedir.
Endometrial cancer (EC) is the most common gynecological malignancy in developed countries. Obesity is known as the major ris k factor for endometrial cancer. The most common subtype of endometrial cancer is endometrioid endometrial carcinoma (EEC). Our stu dy aims to investigate the demographic and clinicopathological characteristics of metastatic EEC patients and the effect of treatments on survival. The median age of the patients was 58 (39.4 -81.9) years. Sixteen patients presented with abnormal vaginal bleeding. The median follow-up time was 43 (0.2-104.3) months. The median progression-free survival (PFS) was 39.9 months (95% confidence interval (CI): 35.0-79.1), and the median overall survival (OS) was 59.1 months (95% CI: 39.1-80.8). Patients receiving chemoradiotherapy had significantly longer PFS and OS than patients treated with chemotherapy alone (log-rank test, p=0.012 for PFS, p=0.015 for OS). Our study supports that chemoradiotherapy might be a treatment option for selected patient groups in the metastatic stage.
Endometrial cancer (EC) is the most common gynecological malignancy in developed countries. Obesity is known as the major ris k factor for endometrial cancer. The most common subtype of endometrial cancer is endometrioid endometrial carcinoma (EEC). Our stu dy aims to investigate the demographic and clinicopathological characteristics of metastatic EEC patients and the effect of treatments on survival. The median age of the patients was 58 (39.4 -81.9) years. Sixteen patients presented with abnormal vaginal bleeding. The median follow-up time was 43 (0.2-104.3) months. The median progression-free survival (PFS) was 39.9 months (95% confidence interval (CI): 35.0-79.1), and the median overall survival (OS) was 59.1 months (95% CI: 39.1-80.8). Patients receiving chemoradiotherapy had significantly longer PFS and OS than patients treated with chemotherapy alone (log-rank test, p=0.012 for PFS, p=0.015 for OS). Our study supports that chemoradiotherapy might be a treatment option for selected patient groups in the metastatic stage.
Description
Keywords
Endometrioid endometrial karsinom, Metastaz, Kemoradyoterapi, Sağkalım, Endometrioid endometrial carcinoma, Metastasis, Chemotherapy, Chemoradiotherapy, Survival, Kemoterapi
Citation
Ocak, B. vd. (2022). "Metastatik endometrioid endometrial karsinom hastalarında tedavi seçeneklerinin sağkalım üzerine etkisi". Uludağ Üniversitesi Tıp Fakültesi Dergisi, 48(1), 37-41.